Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17768575 | 0.98 | ANPEP (0.42) | ANPEPSLC18A3P2RX7OPRL1OPRD1 | |
| SCHEMBL6101290 | 0.74 | DRD2 (0.35) | OPRL1OPRD1CYP3A4CYP2D6CXCR4 | |
| SCHEMBL19043677 | 0.72 | OPRL1 (0.40) | OPRL1OPRD1KCNH2 | |
| SCHEMBL8360537 | 0.70 | CYP19A1 (0.35) | P2RX7 | |
| SCHEMBL17768588 | 0.70 | P2RX7 (0.45) | SLC18A3P2RX7OPRL1 | |
| SCHEMBL12206861 | 0.70 | OPRL1 (0.37) | OPRL1OPRD1KCNH2 | |
| SCHEMBL14016085 | 0.69 | SLC18A3 (0.40) | SLC18A3P2RX7 | |
| SCHEMBL14267785 | 0.69 | SLC18A3 (0.40) | SLC18A3P2RX7 | |
| SCHEMBL17778262 | 0.69 | DPP8 (0.34) | SLC18A3P2RX7OPRL1KCNH2 | |
| SCHEMBL12801168 | 0.69 | OPRL1 (0.43) | P2RX7OPRL1CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | ADORA2A, ADORA1, ADORA3 | ANPEP 2805/4885SLC18A3 269/4885P2RX7 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.